CytomX Therapeutics to Present at Upcoming November Investor Conferences
November 01 2023 - 8:00AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated, localized biologics, today announced that
management will participate in the following investor conferences
in November.
BMO Biopharma Spotlight Series: Oncology Day
Date: Wednesday, November 8, 2023 Fireside Chat: 1:30 p.m. ET
Location: Virtual
Jefferies London Healthcare Conference Date:
Thursday, November 16, 2023 Fireside Chat: 2:00 p.m. GMT Location:
London, UK
Piper Sandler Healthcare Conference Date:
Wednesday, November 29, 2023 Fireside Chat: 11:30 a.m. ETLocation:
New York, NY
Live webcasts of the Jefferies London and Piper Sandler
Healthcare Conference fireside chats will be available on the
Events and Presentations page of CytomX’s website at
www.cytomx.com. In addition, management will be available for
one-on-one meetings with investors who are registered to attend the
conferences.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company focused
on developing novel conditionally activated biologics localized to
the tumor microenvironment. By pioneering a novel class of
conditionally activated biologics, powered by its Probody®
technology platform, CytomX’s goal is to transcend the limits of
current cancer treatments. CytomX’s robust and differentiated
pipeline comprises therapeutic candidates across multiple treatment
modalities including antibody-drug conjugates (“ADCs”), T-cell
engaging bispecific antibodies, and immune modulators such as
cytokines and checkpoint inhibitors. CX-2029 is an investigational
conditionally activated ADC directed toward CD71. CytomX’s clinical
pipeline also includes cancer immunotherapeutic candidates against
validated targets such as the CTLA-4-targeting Probody therapeutic
BMS-986288, partnered with Bristol Myers Squibb, and CX-904, a
conditionally activated T-cell-engaging bispecific antibody
targeting the epidermal growth factor receptor (EGFR) on tumor
cells and the CD3 receptor on T cells, partnered with Amgen. In
addition, CytomX has a diverse preclinical portfolio of
wholly-owned assets including CX-801, an interferon alpha-2b
Probody cytokine that has broad potential applicability in
traditionally immuno-oncology sensitive as well as insensitive
(cold) tumors and CX-20511, a conditionally activated ADC directed
toward EpCAM, with potential applicability across multiple
EpCAM-expressing epithelial cancers. CytomX has also established
strategic collaborations with multiple leaders in oncology,
including Amgen, Astellas, Bristol Myers Squibb, Regeneron and
Moderna. For more information about CytomX and how it is
working to make conditionally activated treatments the new
standard-of-care in the fight against cancer, visit www.cytomx.com
and follow us on LinkedIn and Twitter.
Probody is a U.S. registered trademark of CytomX Therapeutics,
Inc.
CytomX Contact:Chris OgdenSVP,
Finance and Accounting cogden@cytomx.comDirect: (317) 767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
1 Licensed from Immunogen
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Apr 2024 to May 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From May 2023 to May 2024